[Persistence of hypercoagulability state after hip and knee arthroplasty: what is the optimal duration of antithrombotic guidelines in this surgery?].

Abstract

Among 79 patients candidates to hip (53) and knee (26) replacement an evaluation was made of the influence of a two-week program with LMWH on the evolution of hypercoagulability markers: D-D, TAT, and F1 + 2. Measurements were performed by ELISA preoperatively and on days 1, 7 and about 45 postoperatively; in the latter, two extraction intervals were considered: < or = 45 days and > 45 days. With both surgical modalities, D-D and F1 + 2 peaked at 7th day postoperatively, whereas TAT peaked on day 1. Among D-D and F1 + 2 values quantitated on day 7th and the extraction interval < or = 45 days, no significant differences were obtained (Z < 2.64). The hypercoagulative chronicity exhibited by D-D and F1 + 2 during the first month and a half after this surgery, might require in some cases a more prolonged thromboprophylaxis.

• Authors: T Iturbe Hernández, R Cornudella Lacasa, R de Miguel Olmeda, G Azaceta Reinares, M A Fuertes Palacio, F Seral Iñigo, M Gutiérrez Martín
• Journal: Revista clinica espanola (Rev Clin Esp) Vol. 199 Issue 8 Pg. 511-6 (Aug 1999) ISSN: 0014-2565 [Print] Spain
• Vernacular Title: Persistencia del estado de hipercoagulabilidad tras artroplastia de cadera y rodilla: cuál debe ser la duración óptima de las pautas antitrombóticas en esta cirugía?
• PMID: 10522431 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Biomarkers
• Blood Coagulation Factors
• Fibrinolytic Agents
• antithrombin III-protease complex
• Antithrombin III
• Peptide Hydrolases

Topics

• Aged
• Antithrombin III (analysis)
• Arthroplasty, Replacement, Hip (adverse effects)
• Arthroplasty, Replacement, Knee (adverse effects)
• Biomarkers
• Blood Coagulation Factors (analysis)
• Enzyme-Linked Immunosorbent Assay
• Female
• Fibrinolytic Agents (administration & dosage)
• Humans
• Male
• Middle Aged
• Peptide Hydrolases (analysis)
• Thrombophilia (diagnosis, drug therapy, etiology)
• Time Factors